New York Failure-to-Warn Allergic Reaction Lawsuits: When Manufacturers Are Liable for Catastrophic Injuries
- Reza Yassi
- Jul 20
- 9 min read
A Nassau County electrician picks up a box of drugstore hair dye on the way home from a job in Mineola. Forty minutes after applying it, his scalp is blistering, his face has swollen past recognition, and his wife is driving him to a Long Island emergency room, where he's treated for a severe chemical reaction and airway swelling. The box named the ingredients. It said nothing about what those ingredients could do. Whether he has a viable New York failure-to-warn allergic reaction case worth six figures, seven, or nothing at all turns on rules most people never think about until an ambulance is already rolling.
Our firm handles catastrophic injuries: severe chemical burns, anaphylaxis, Stevens-Johnson syndrome, permanent scarring, and wrongful death. This post walks through when a manufacturer in New York owes you a warning about an allergic or chemical reaction, when the courts will slam the door, and how experienced plaintiffs' lawyers get around the defenses that manufacturers raise reflexively.
When Can You Sue a New York Manufacturer for a Catastrophic Allergic Reaction?
You can sue in New York when a consumer product causes a serious injury, the manufacturer knew or should have known its product could cause that kind of reaction, and a proper warning would have changed what happened. That three-part test comes from the Court of Appeals decision in Rastelli v. Goodyear Tire & Rubber Co., 79 N.Y.2d 289 (1992), and it governs every failure-to-warn allergic reaction claim in the state, whether the product is a shampoo, a hair dye, a household cleaner, a bedsheet, an implanted medical device, or a restaurant menu item.
Two things drive value in these cases: how catastrophic the injury is, and how strong the foreseeability record is. A rash that clears in three days rarely justifies litigation. But airway swelling that requires intubation, chemical burns that need skin grafts, anaphylaxis that causes an anoxic brain injury, or Stevens-Johnson syndrome triggered by a drug or cosmetic ingredient. Those cases can be worth well into seven figures. Stevens-Johnson syndrome and toxic epidermal necrolysis can be fatal in a significant share of severe adult cases, and survivors often need weeks of burn-unit-style care. Our companion post on severe burn injury lawsuits in New York walks through the compensation categories these cases generate.
The catastrophic-injury angle matters legally, not just financially. Insurance adjusters brush off "hives from moisturizer" complaints; they negotiate seriously when there's an ICU stay at Weill Cornell, a permanent scar on a face or hand, or a treating physician willing to link the reaction directly to the ingredient. New York judges also look harder at the merits of a failure-to-warn allergic reaction claim when the harm is life-altering, because the equities push toward giving the plaintiff a shot at the jury rather than granting summary judgment. If you want a broader map of how these claims fit into New York's products framework, we cover the fundamentals in our post on New York product liability actions.
What Must You Prove in a New York Failure-to-Warn Allergic Reaction Case?
You must prove three things: a hidden danger the manufacturer knew or reasonably should have known about, a warning that was missing or inadequate, and a causal link showing that a proper warning would have prevented the injury. This is the Rastelli test, and each element is where the case is won or lost.
The "hidden danger" prong requires more than a bad reaction. Under Rastelli, a manufacturer has a duty to warn about "latent dangers resulting from foreseeable uses of its products of which it knew or should have known." That knowledge can come from many sources: the manufacturer's own complaint database, FDA classifications, EPA hazard listings, medical literature, competitor product labels, or a chain of prior lawsuits. The U.S. Food and Drug Administration publishes ingredient and allergen data for cosmetics; if the ingredient your client reacted to already sits on a federal watchlist, foreseeability is halfway proven before you file.
The "inadequate warning" prong is fact-specific. Naming an ingredient in tiny print on the back of the box is not always enough. The First Department in Mulhall v. Hannafin, 45 A.D.3d 55 (1st Dep't 2007), emphasized that a warning must convey the "most current knowledge available" of the risks associated with the product. If a competitor's label says "may cause severe skin reactions in some users; discontinue if rash develops" and your defendant's label just recites the chemical name, that gap is your case. For prescription drugs and implanted medical devices, the warning goes to the doctor under New York's learned-intermediary rule, so you'll also be reading package inserts and dear-doctor letters as part of your inadequacy proof.
The third prong — causation — is the trap. New York requires you to prove that if a proper warning had been given, your client would have read it, understood it, and acted on it. Sosna v. American Home Products, 298 A.D.2d 158 (1st Dep't 2002), makes clear that a warning is legally meaningless when the injured person wouldn't have heeded it. In Mulhall, the plaintiff admitted she never read the surgical consent forms and would have proceeded with the operation regardless, and that admission alone killed her failure-to-warn claim on appeal. So ask your client on day one: did you read the label? Do you routinely check for allergens? Have you avoided products before because of ingredient disclosures? Their honest answers make or break the causation element long before a defense expert ever sees the file.
When Does the "Rare-Allergy Rule" Block a New York Failure-to-Warn Claim?
The rare-allergy rule blocks the claim when the injury results from an idiosyncratic sensitivity that only an "insignificant percentage of the population" would share. That language comes from Kaempfe v. Lehn & Fink Products Corp., 21 A.D.2d 197 (1st Dep't 1964), affirmed at 20 N.Y.2d 818 (1967). Kaempfe is the case every defense lawyer in New York cites first, and every plaintiff's lawyer needs a ready answer for it.
The rule is straightforward. A manufacturer of a product that's safe for the general population isn't required to warn "the unknown few" who might have a hypersensitive reaction. The plaintiff in Kaempfe developed severe dermatitis from a deodorant, but the court held that a warning would have been meaningless to a person who didn't already know she carried the allergy. Similarly, in Pai v. Springs Industries, Inc., 18 A.D.3d 529 (2d Dep't 2005), a bedsheet manufacturer prevailed on summary judgment against a plaintiff who developed a formaldehyde reaction because no other customer had ever complained, the plaintiff was the only reported case, and no alternative design existed that eliminated the formaldehyde. The Second Department was blunt: without commonality and without a safer design, there's no duty to warn.
The rule has real teeth across industries — cosmetics, textiles, food, over-the-counter drugs, even restaurant meals. A recent Southern District decision, Manz v. LTN1 Times Square, LLC (S.D.N.Y. Feb. 15, 2026), dismissed a diner's negligence claim over a burning reaction to salsa on essentially the same theory: no prior complaints, no evidence the product exceeded customary norms for its category, and no evidence the diner would have avoided the salsa even with a spice-level warning. It's a reminder that "I had a reaction" is a starting point, not a case.
But Kaempfe has real limits, and understanding those limits is where plaintiff's-side skill lives. The defense protects manufacturers only when three things are true: the ingredient is not a known allergen at meaningful population levels; no prior reports or complaints have put the manufacturer on notice; and no safer alternative existed. Knock out any one of those pillars, and the defense collapses. That's exactly what happened in the case discussed next.
How Do You Prove a New York Manufacturer Should Have Foreseen the Allergic Reaction?
You prove foreseeability by attacking every pillar of the rare-allergy defense and by building an evidentiary record that matches the theory the federal Eastern District accepted in Candelaria v. Conopco, Inc., No. 21-CV-6760 (E.D.N.Y. Feb. 28, 2023). Candelaria is the case plaintiffs' lawyers cite most often now for keeping a failure-to-warn allergic reaction claim alive past a motion to dismiss.
The Candelaria plaintiff alleged that her TRESemmé shampoo caused her hair to fall out because of a preservative called DMDM hydantoin, which slowly releases formaldehyde. Unilever moved to dismiss under Kaempfe, arguing that any reaction was a personal idiosyncrasy. The court denied the motion because the complaint alleged four things that took the case out of Kaempfe:
DMDM is classified by the FDA as one of the most common cosmetic allergens.
Scientific literature has documented DMDM as a direct skin irritant — meaning it can cause irritant contact dermatitis in any person with enough exposure, not only in people with a preexisting allergy.
Unilever had received prior consumer complaints and had already been sued three times over the same ingredient.
Several competitors had already removed DMDM from their formulas, proving a safer alternative was commercially feasible.
That is the template. To beat Kaempfe, you need to show that the ingredient hurts more than a statistically insignificant slice of the population, that the manufacturer had actual or constructive notice through prior complaints or regulatory data, and that a reformulation was practical. The National Library of Medicine's PubMed database is your friend for peer-reviewed research; the FDA's MedWatch adverse event reporting system is your friend for prior-complaint records. Discovery of the manufacturer's own internal complaint files often produces the strongest evidence, because most companies keep them, even when a report never makes it into an FDA filing. If the causation story requires connecting exposure to a systemic injury, the Court of Appeals opinion we discuss in our post on Nemeth v. Brenntag and toxic tort causation in New York is required reading.
Experienced lawyers watch for one more angle: express warranty language on the packaging. When a product is marketed as "hypoallergenic," "gentle for sensitive skin," "non-toxic," or "dermatologist-tested," that marketing creates its own claim under New York law and directly undermines the Kaempfe defense — a manufacturer can't invoke idiosyncratic sensitivity in defense while its front label promises the opposite. Most claimants miss that the label copy is often more valuable than the ingredient list.
There's a second tactical point. Experienced lawyers preserve the intact packaging and the receipt on day one. The label version controls the failure-to-warn analysis, and manufacturers routinely revise wording between production runs. If the label your client actually saw isn't in evidence, the defense will produce a later, more comprehensive version and argue the case away. Product cases involving lithium-ion or high-energy consumer devices raise the same preservation challenge; our discussion of NYC lithium-ion battery fire injuries covers similar spoliation issues on the device side.
Finally, watch the statute of limitations. Most personal-injury product cases run under the standard three-year clock at CPLR § 214. Consumer-facing companies that mislead about ingredient safety may also face parallel claims under GBL § 349, New York's deceptive-practices statute — a route the Candelaria plaintiff also used to broaden the case.
What Do New Yorkers Ask Most Often After a Catastrophic Allergic Reaction?
The questions we hear from clients across NYC and Long Island track a predictable pattern. They usually come up on the first call, sometimes from a hospital bed at NYU Langone or Long Island Jewish. Here are the ones that come up most often.
Do I have a case if the ingredient was listed on the label?
Sometimes yes. Listing an ingredient is not automatically an adequate warning under New York law. The First Department in Mulhall v. Hannafin held that a warning must convey current known risks, not just identify the chemical. If the label says "contains DMDM hydantoin" but not "may cause severe hair loss or dermatitis with prolonged use," and the manufacturer had prior complaints or knew of scientific literature identifying the risk, that gap can support a triable failure-to-warn allergic reaction claim.
What if my doctor never diagnosed a specific allergen?
You may still have a case, but it becomes harder. New York cases like Candelaria accept that some ingredients act as direct irritants that harm anyone with sufficient exposure, not only people with a pre-existing allergy. A treating dermatologist or a toxicologist who can link the injury to the ingredient, even without formal patch testing, often bridges the gap. Save the product, the packaging, and every medical record from the reaction visit forward.
How long do I have to file a New York product liability lawsuit?
Generally three years from the date of injury under CPLR § 214, though wrongful death claims run two years from the date of death, and toxic exposure cases have their own discovery-rule accrual under CPLR § 214-c. Don't wait. Product cases require chemical testing, industry-standard reviews, and preserved packaging, and a delayed filing often means lost physical evidence and a much weaker liability picture.
What kinds of damages can a catastrophic allergic reaction case recover in New York?
Full economic damages (past and future medical bills, lost earnings, home modifications for scarring or respiratory limitations), non-economic damages (pain and suffering, loss of enjoyment of life, disfigurement), and in cases of reckless corporate conduct, punitive damages. Six-figure and seven-figure recoveries are realistic when the injury involves permanent scarring, respiratory compromise, or long-term skin conditions. Our post on structured settlements in New York catastrophic injury cases discusses how larger settlements are arranged to protect a client's long-term care.
The Bottom Line
A failure-to-warn allergic reaction claim in New York isn't a slam-dunk, and it isn't a lost cause. It's a case-by-case analysis of the ingredient, the manufacturer's knowledge, the label, and the injury. The catastrophic injuries are where the real value is, and the rare-allergy defense collapses when you can show foreseeability, prior notice, and a commercially feasible safer alternative.
If you or someone you know has suffered a catastrophic injury from an allergic or chemical reaction to a consumer product, the team at Yassi Law P.C. is ready to help. Call us today at 646-992-2138 for a consultation.
.png)